Plus, Company Advances Plans for Phase 2b Trial in 2022
SAN DIEGO–(BUSINESS WIRE)–Today, MediPrint™ Ophthalmics, an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight, announces the acceptance and presentation of a poster highlighting its latest clinical results at the upcoming Global Specialty Lens Symposium (GSLS), a leading eye care conference. The poster spotlights the results of the company’s SIGHT-1 Phase 2a clinical study and its inclusion in this meeting confirms the high level of interest in the eye care industry in drug delivery contact lenses. The SIGHT-1 study demonstrated the safety and tolerability of the company’s lead asset, LL-BMT1, a weekly medicated contact lens releasing bimatoprost to treat open angle glaucoma and ocular hypertension. The poster also delves into the improved dryness scores observed over the seven-day wear period as well as the efficacy signals seen in the study.
“It’s exciting to see the work MediPrint Ophthalmics has done so far and to know that the once futuristic idea of contact lens drug delivery is on the cusp of becoming a reality,” said Dr. Melissa Barnett, OD, FAAO, FSLS, FBCLA, principal optometrist at the University of California, Davis Eye Center and author of the GSLS poster. “Drug delivery contact lens innovations could mark a significant advancement for eye care and I look forward to presenting the poster to my colleagues at GSLS.”
“The concept of contact lens drug delivery has been around for decades,” added Dan Myers, CEO of MediPrint Ophthalmics. “We are enthused to be the first to have brought a product for glaucoma to the clinic for human trials. It is rewarding to see a preeminent professional conference in our field recognize and validate our advancements and the commercial potential of our proprietary solution. We are excited to continue the SIGHT clinical program while we also bring other assets in our pipeline to the IND stage.”
Additionally, the company is pleased to announce its upcoming SIGHT-2 Phase 2b clinical study in India. Regulatory submissions were received by the Drug Controller General of India in December 2021. The company expects to begin the study in the second quarter of 2022. SIGHT-2 is a dose-escalation study designed to measure IOP reductions from three different doses of LL-BMT1 versus a control arm of traditional eye drops. The company is confident one of the doses to be evaluated will show the combined efficacy and safety required to give it confidence to advance LL-BMT1 to Phase 3 trials.
About MediPrint™ Ophthalmics
MediPrint™ Ophthalmics (formerly Leo Lens Pharma) is an emerging San Diego-based clinical stage eye care pharmaceutical company focused on helping protect sight by developing and commercializing a proprietary ocular drug delivery portfolio. The Company is currently advancing its lead asset, a unique and complete glaucoma treatment, to the clinic while continuing to build out its product portfolio for dry eye and for allergy, and subsequently for other anterior and posterior segment conditions. Using its proprietary MediPrint process, MediPrint Ophthalmics will initially commercialize a drug-eluting, comfort-enhancing, preservative-free contact lens to treat millions of glaucoma patients worldwide. While eye drops have been around for over 40 years and remain the standard of care for over 90% of patients, they have only around a 50% compliance rate. This leads millions to suffer from disease progression and thousands to suffer from preventable blindness. There is a large unmet need for a better non-invasive treatment option in this $4B U.S. market. MediPrint Ophthalmics’ patented MediPrint process offers a unique value proposition for patients, practitioners, strategic partners, and payers.
For more information, please visit www.mediprintlens.com.
Contacts
Company Contact:
Kenny Key
MediPrint Ophthalmics, Inc.
858-522-0815
kkey@mediprintlens.com
Media Contact:
Orlando Rodrigues
COR Communications
760-212-5727
orodrigues@mediprintlens.com